Sector
PharmaceuticalsOpen
₹3.3Prev. Close
₹3.45Turnover(Lac.)
₹0.29Day's High
₹3.3Day's Low
₹3.352 Week's High
₹052 Week's Low
₹0Book Value
₹-14.82Face Value
₹2Mkt Cap (₹ Cr.)
39.25P/E
2.01EPS
1.6Divi. Yield
0
| Y/e 31 Mar( In .Cr) | Mar-2016 | Jun-2015 | Jun-2014 | Jun-2013 |
|---|---|---|---|---|
Equity Capital | 37.51 | 37.51 | 101.67 | 65.31 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -219 | 80.57 | 242.27 | 178.62 |
Net Worth | -181.49 | 118.08 | 343.94 | 243.93 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2016 | Jun-2015 | Jun-2014 | Jun-2013 |
|---|---|---|---|---|
Revenue | 253.45 | 833.95 | 1,313.76 | 1,059.49 |
yoy growth (%) | -69.6 | -36.52 | 23.99 | 34.95 |
Raw materials | -332.25 | -808.49 | -1,112.74 | -902.07 |
As % of sales | 131.08 | 96.94 | 84.69 | 85.14 |
Employee costs | -16.54 | -19.82 | -18.87 | -14.31 |
| Y/e 31 Mar( In .Cr) | Mar-2016 | Jun-2015 | Jun-2014 | Jun-2013 |
|---|---|---|---|---|
Profit before tax | -217.88 | -144.56 | 84.75 | 66.18 |
Depreciation | -15.01 | -19.16 | -15.35 | -12.12 |
Tax paid | -9.96 | -4.66 | -15.13 | -13.33 |
Working capital | -262.07 | -118.82 | 152.7 | 135.55 |
Other operating items |
| Y/e 31 Mar | Mar-2016 | Jun-2015 | Jun-2014 | Jun-2013 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -69.6 | -36.52 | 23.99 | 34.95 |
Op profit growth | 289.25 | -121.89 | 30.35 | 26.46 |
EBIT growth | 188.51 | -135.51 | 31.24 | 25.08 |
Net profit growth | 32.47 | -424.43 | 31.7 | 27.02 |
| Particulars (Rupees in Crores.) | Mar-2016 | Jun-2015 | Jun-2014 | Jun-2013 | Jun-2012 |
|---|---|---|---|---|---|
Gross Sales | 253.45 | 838.46 | 1,324.79 | 1,073.52 | 804.14 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 253.45 | 838.46 | 1,324.79 | 1,073.52 | 804.14 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 1.95 | 2.63 | 1.92 | 1.19 | 1.24 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,744.8 | 132.89 | 4,18,647.96 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,025.5 | 76.85 | 1,59,310.35 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,480 | 25.66 | 1,19,409.63 | 1,438.15 | 0.88 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,141.2 | 58.21 | 1,06,184.18 | 485 | 0.89 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,408.2 | 51.49 | 99,569.64 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Savita Gowda
Whole-time Director
Lalit Misra
Director
Nivedita Patil
Director
Harish Palecanda
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Sharon Bio-Medicine Ltd
Summary
Incorporated in 1989,Sharon Bio-Medicine Ltd is engaged in the pharmaceuticals/chemicals segment.The company had developed a number of products in active pharmaceutical ingredient (API), intermediates and formulations. During the fiscal year ended June 30, 2010, it had set up an active pharmaceutical ingredients plant in Taloja near Navi Mumbai.The company had installed capacity of 150,000 liters of reactors capacity of API and intermediates, and 2.5 billion tablets per shift per annum and one billion capsules per shift per annum. Its products include Trimetazidine Di Hydrochloride, Ketoconzole, Pentaprazole, Amlodipine Besylate, Atomoxetine Hcl, Carisoprodl, Closantel Base, Glimepiride, Ketoconazole, Nifedipibe, Racecadotril, Toldimfos, Telmisartan, Tamsulosin, Itraconazole, Mesalazine, Lansoprazole and Doxorubicin Inj.In January 2010,the Company started its toxicology laboratory and research and development unit at Taloja, Navi Mumbai.
Read More
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
